The role of methotrexate and low‐dose prednisolone on adiponectine levels and insulin resistance in patients with rheumatoid arthritis naïve to disease‐modifying antirheumatic drugs

Publisher： John Wiley & Sons Inc

E-ISSN： 1756-185x|19|7|665-671

ISSN： 1756-1841

Source： INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (ELECTRONIC), Vol.19, Iss.7, 2016-07, pp. : 665-671

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease‐Modifying Antirheumatic Drugs

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 12, 2015-12 ,pp. : 1671-1678

John Wiley & Sons Inc

Access to resources Recommend Favorite

Medication Persistence of Disease‐Modifying Antirheumatic Drugs and Anti–Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil

By  

ARTHRITIS CARE AND RESEARCH, Vol. 68, Iss. 10, 2016-10 ,pp. : 1489-1496

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tofacitinib with conventional synthetic disease‐modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient‐reported outcomes from a Phase 3 randomized controlled trial

By  

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (ELECTRONIC), Vol. 21, Iss. 2, 2018-02 ,pp. : 402-414

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial: Inflammation, Disease‐Modifying Antirheumatic Drugs, Lipids, and Cardiovascular Risk in Rheumatoid Arthritis

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 2, 2015-02 ,pp. : 327-329

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use and Spending for Biologic Disease‐Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 9, 2015-09 ,pp. : 1210-1218

John Wiley & Sons Inc

Access to resources Recommend Favorite